{"prompt": "['4.6.2', 'Study Treatment Discontinuation', 'Patients must discontinue emicizumab if they experience any of the following:', 'Pregnancy', \"Any medical condition that the investigator or Sponsor determines may jeopardize the patient's\", 'safety if he or she continues to receive emicizumab', 'Investigator or Sponsor determines it is in the best interest of the patient', 'Requirement of another medication not permitted per protocol', 'The primary reason for emicizumab discontinuation should be documented on the appropriate', 'eCRF. Patients who discontinue emicizumab prematurely will not be replaced. Patients who', 'become pregnant should immediately discontinue treatment and be managed according to', 'local guidelines.', '4.6.3', 'Study and Site Discontinuation', 'The Sponsor has the right to terminate this study at any time. Reasons for terminating the', 'study may include, but are not limited to, the following:', 'The incidence or severity of adverse events in this or other studies indicates a potential', 'health hazard to patients', 'Patient enrollment is unsatisfactory.', 'The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.', 'The Sponsor has the right to close a site at any time. Reasons for closing a site may include,', 'but are not limited to, the following:', 'Excessively slow recruitment', 'Poor protocol adherence (e.g., bleed/medication data not checked by investigator/co-', 'investigator for > 8 weeks)', 'Inaccurate or incomplete data recording', 'Non-compliance with the International Conference on Harmonisation (ICH) guideline for', 'Good Clinical Practice', 'No study activity (i.e., all patients have completed the study and all obligations have', 'been fulfilled).', '5.', 'ASSESSMENT OF SAFETY', '5.1', 'SAFETY PLAN', 'Emicizumab is not approved in all countries, and clinical development is still ongoing. The', 'safety plan for patients in this study is based on clinical experience with emicizumab in', 'completed and ongoing studies. The anticipated important safety risks for emicizumab are', \"outlined below. Please refer to the emicizumab Investigator's Brochure for a complete\", 'summary of safety information.', 'Several measures will be taken to ensure the safety of patients participating in this study.', 'Eligibility criteria have been designed to exclude patients at high risk for toxicities. Patients', 'Emicizumab - F. Hoffmann-La Roche Ltd', '125 / Protocol MO39129, Version 3']['will undergo safety monitoring during the study, including assessment of the nature,', 'frequency, and grade of adverse events. In addition, guidelines for managing adverse events,', 'including criteria for dosage modification and treatment interruption or discontinuation, are', 'provided below.', '5.1.1', 'Risks Associated with Emicizumab', '5.1.1.1', 'Injection-Site Reactions', 'In the completed and ongoing Japanese studies, ISRs have been observed in some patients', 'with hemophilia A. These local ISRs included injection-site erythema, injection-site', 'hematoma, injection-site rash, injection-site discomfort, injection-site pain, and injection-site', 'pruritus. All local ISRs were of mild intensity. Further details on the observed ISRs are', \"available in the Investigator's Brochure. To minimize the risk for ISRs, emicizumab should be\", 'injected subcutaneously using separate injection sites as described in Sections 0 and 0 and', 'the IFU document.', '5.1.1.2', 'Hypercoagulation and Thromboembolic Events', 'As of April 2017, there have been two serious thrombotic events reported in two patients who', 'were treated with bypassing agents while receiving emicizumab prophylaxis in Study BH29884.', 'One patient self-administered greater than 200 units/kg/day of aPCC for two consecutive', 'days and developed cavernous sinus thrombosis. Treatment with emicizumab was', 'interrupted, no further aPCC was administered, and the clot resolved without', 'anticoagulation in approximately 2.5 weeks. Emicizumab was restarted after', 'approximately 10 days after the resolution of the serious adverse event without recurrence.', 'The second patient developed severe skin necrosis (both legs) and contemporaneous', 'superficial vein thrombosis in the right leg after self-administering two consecutive doses', 'of 100 units/kg/day of aPCC. The patient recovered on supportive therapy (no', \"anticoagulation). For more details please refer to the emicizumab Investigator's Brochure.\", 'All thromboembolic events should be reported as adverse events of special interest (see', 'Section 5.2.3), and also as serious adverse events if it meets criteria as described in Section 5.2.2.', 'HCPs should educate patients/caregivers to recognize signs and symptoms of potential', 'thromboembolism or thrombosis (i.e., dyspnea, chest pain, leg pain or swelling; or if in the head,', 'headache, numbness in the face, eye pain or swelling, or vision impairment; or if in the skin,', 'blackening and associated pain) and ensure that they understand the importance of seeking', 'appropriate medical attention. Patients and/or caregivers will also receive two alert cards to', 'remind them of this information should thromboembolism be suspected.', '5.1.1.3', 'Thrombotic Microangiopathy', 'TMA is used to describe a group of disorders with clinical features of microangiopathic', 'hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys,', 'gastrointestinal system, central nervous system. As of April 2017, three cases of TMA were', 'observed in Study BH29884 involving patients with hemophilia A with inhibitors who were treated', 'with bypassing agents while receiving emicizumab.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '126 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}